Adial Pharmaceuticals, Inc. Cash Provided by (Used in) Operating Activities, Discontinued Operations
Adial Pharmaceuticals, Inc. (ADIL) reported Cash Provided by (Used in) Operating Activities, Discontinued Operations of -$1.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations · last filed 2025-03-04
- Adial Pharmaceuticals, Inc. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2023-12-31 was -$17.59K.
- Adial Pharmaceuticals, Inc. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2023-09-30 was $0.00.
- Adial Pharmaceuticals, Inc. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2022-12-31 was -$346.44K.
- Adial Pharmaceuticals, Inc. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2022-09-30 was -$928.09K.
- Adial Pharmaceuticals, Inc. cash provided by (used in) operating activities, discontinued operations for fiscal 2023 was -$1.00M.
- Adial Pharmaceuticals, Inc. cash provided by (used in) operating activities, discontinued operations for fiscal 2022 was -$2.59M.
| Period end | Cash Provided by (Used in) Operating Activities, Discontinued Operations 3 month | Cash Provided by (Used in) Operating Activities, Discontinued Operations 6 month | Cash Provided by (Used in) Operating Activities, Discontinued Operations 9 month | Cash Provided by (Used in) Operating Activities, Discontinued Operations 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$17.59K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$17.59K derived: sum of 2 quarters · filed 2025-03-04 | -$1.00M 10-K · filed 2025-03-04 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$985.86K 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | -$985.86K 10-Q · filed 2024-08-13 | |||
| 2022-12-31 | -$346.44K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$1.27M derived: sum of 2 quarters · filed 2024-04-01 | -$2.59M 10-K · filed 2024-04-01 | |
| 2022-09-30 | -$928.09K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-14 | -$2.25M 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | -$1.32M 10-Q/A · filed 2023-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |